POLBF (Poolbeg Pharma) Buyback Yield %: -9.41 (As of Jun. 29, 2026)


What is Poolbeg Pharma Buyback Yield %?

Poolbeg Pharma POLBF Buyback Yield % is -9.41 as of Jun. 29, 2026. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, Poolbeg Pharma ranks worse than 50.13% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Poolbeg Pharma's current buyback yield was -9.41%.

Poolbeg Pharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Buyback Yield % Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 0.00 -20.23

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 -19.50 -16.05

POLBF vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Poolbeg Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Buyback Yield % falls into.


Poolbeg Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Poolbeg Pharma's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 5.993) / 29.631
=-20.23%

Poolbeg Pharma's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 5.993) / 29.631
=-20.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -9.41 mean?
Poolbeg Pharma (POLBF) has a Buyback Yield % of -9.41 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #372 out of 742 companies in the Biotechnology industry, placing it in the top 50.1%.
Is Poolbeg Pharma's Buyback Yield % too high?
Poolbeg Pharma's current Buyback Yield % is -9.41. Based on the distribution chart, Poolbeg Pharma ranks #372 out of 742 companies in the Biotechnology industry, which is below the industry midpoint.
How does Poolbeg Pharma's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #372 out of 742 companies for Buyback Yield %. This places Poolbeg Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Buyback Yield % is -9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Buyback Yield % of -9.41. The current Buyback Yield % is -9.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Buyback Yield % is -9.41 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.